share_log

Clearmind Medicine | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(4.99%),Daniel B. Asher(4.99%), etc.

Clearmind Medicine | SC 13G/A:超过5%持股股东披露文件(修正)-Mitchell P. Kopin(4.99%),Daniel B. Asher(4.99%)等

SEC announcement ·  02/06 09:57
Moomoo AI 已提取核心信息
An amendment to Schedule 13G has been filed with the United States Securities and Exchange Commission by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, reporting a change in their holdings of Clearmind Medicine Inc. common shares. As of December 31, 2023, the reporting persons collectively hold 88,925 shares, representing approximately 4.99% of the company's common stock. This ownership includes shares issuable upon the exercise of two warrants held by Intracoastal Capital LLC. The amendment, filed on February 6, 2024, indicates that the shares were not acquired for the purpose of changing or influencing the control of Clearmind Medicine Inc. and are not held in connection with any transaction having that purpose or effect.
An amendment to Schedule 13G has been filed with the United States Securities and Exchange Commission by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, reporting a change in their holdings of Clearmind Medicine Inc. common shares. As of December 31, 2023, the reporting persons collectively hold 88,925 shares, representing approximately 4.99% of the company's common stock. This ownership includes shares issuable upon the exercise of two warrants held by Intracoastal Capital LLC. The amendment, filed on February 6, 2024, indicates that the shares were not acquired for the purpose of changing or influencing the control of Clearmind Medicine Inc. and are not held in connection with any transaction having that purpose or effect.
米切尔·科平、丹尼尔·阿舍尔和Intracoastal Capital LLC已向美国证券交易委员会提交了附表13G的修正案,报告了他们持有的Clearmind Medicine Inc.普通股的变化。截至2023年12月31日,申报人共持有88,925股股票,约占公司普通股的4.99%。该所有权包括行使Intracoastal LLC持有的两份认股权证后可发行的股份。该修正案于2024年2月6日提交,表明收购这些股份不是为了改变或影响Clearmind Medicine Inc.的控制权,也不是与任何具有该目的或效果的交易有关而持有的。
米切尔·科平、丹尼尔·阿舍尔和Intracoastal Capital LLC已向美国证券交易委员会提交了附表13G的修正案,报告了他们持有的Clearmind Medicine Inc.普通股的变化。截至2023年12月31日,申报人共持有88,925股股票,约占公司普通股的4.99%。该所有权包括行使Intracoastal LLC持有的两份认股权证后可发行的股份。该修正案于2024年2月6日提交,表明收购这些股份不是为了改变或影响Clearmind Medicine Inc.的控制权,也不是与任何具有该目的或效果的交易有关而持有的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息